Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASP-001 is an oral spray formulation of sildenafil, the active ingredient in Viagra. Developed by Aspargo Laboratories using proprietary technology, it is designed for the treatment of erectile dysfunction (ED). The oral spray enables faster absorption—beginning within five minutes—compared to traditional tablet forms. This rapid onset may offer advantages for patients seeking more immediate effects. ASP-001 has received regulatory approval in several countries including Spain, Germany, the Netherlands, Ireland, Mexico, and the United Kingdom. It is marketed under brand names such as HEZKUE (Germany) and BANDOL (Spain). Aspargo Laboratories plans to seek FDA approval in the United States[1][2][3]. The mechanism of action is inhibition of type 5 cyclic nucleotide phosphodiesterase (PDE5), leading to increased blood flow in erectile tissue[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ASP-001.